AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00129337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
Study NCT03474224 — intervention group
Intervention type: DEVICE
Intervention: Ev1000 Clinical Platform from Edwards Lifesciences
Description: The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
Study NCT01126892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT01206465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given IV
Study NCT01206465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01206465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT01206465 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT05301647 — intervention group
Intervention type: OTHER
Intervention: The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)
Description: The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
Study NCT05301647 — intervention group
Intervention type: OTHER
Intervention: Total symptom score (TSS)
Description: Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
Study NCT05301647 — intervention group
Intervention type: OTHER
Intervention: Visual analogic scale (VAS)
Description: A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
Study NCT03667430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porous silica
Description: The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
Study NCT03667430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (microcrystalline cellulose)
Description: All participants starts with five days placebo run in period
Study NCT01392599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)
Description: After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
Study NCT01174576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeinated and decaffeinated coffee
Description: 3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
Study NCT01891214 — intervention group
Intervention type: OTHER
Intervention: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)
Study NCT05567536 — intervention group
Intervention type: DRUG
Intervention: Antiplatelet Agents
Description: Patients who received a single antiplatelet agent will be analyzed according to the prescribed antiplatelet agent
Study NCT02265289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban
Study NCT02265289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT02392520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetrorelix (cetrotide)
Description: 0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
Study NCT02392520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
Study NCT00678613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics and Placebo
Description: The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
Study NCT00678613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics and Norfloxacin
Description: The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
Study NCT03955562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Footbridge
Description: Access to a pedestrian footbridge.
Study NCT03059914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterOss
Description: Anorganic bovine bone mineral - Xenograft
Study NCT03059914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-oss
Description: Anorganic bovine bone mineral ( Xenograft)
Study NCT02461693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200mg delivered as pill; one-time dose
Study NCT02461693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose-based pill; one-time dose
Study NCT03468842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Already described
Study NCT03468842 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00383799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv Amiodarone
Study NCT00383799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iv Procainamide
Study NCT01300403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flutter valve
Description: Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
Study NCT01300403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiration with the glottis open in lateral posture (ELTGOL)
Description: This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
Study NCT01300403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
Study NCT00787826 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Francisella Tularensis Vaccine
Description: Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20.
Study NCT00583648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinanlysis
Description: sending a Urine sample to the laboratory for processing
Study NCT03894358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeFum and 7.5 g prebiotic mixture
Description: The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically.
Study NCT03894358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FeFum and 3 g prebiotic mixture
Description: Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
Study NCT03894358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fefum and no prebiotic mixture
Description: Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
Study NCT00626288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine 800mg t.i.d. 12 weeks
Study NCT00626288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cpr, t.i.d. 12 weeks
Study NCT02024061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Study NCT02024061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular treatment
Description: The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
Study NCT03385733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
Study NCT01099046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep
Study NCT01099046 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lifestyle
Description: water intake, tympanic tubing, regular sleep
Study NCT00873158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study NCT03037840 — intervention group
Intervention type: DEVICE
Intervention: Low intensity amplitude-modulated RF EMFs
Description: Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
Study NCT01100385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ateronon
Description: Tomato extract (lycopene) capsule, taken once daily for 56 days
Study NCT01100385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsule, taken once daily for 56 days
Study NCT03733808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique
Study NCT03733808 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation technique
Study NCT01005238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Study NCT01005238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg tablet once per day for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg tablet once per day for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg DIO-902 tablet once daily for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DIO-902 placebo
Description: DIO-902 placebo tablet once daily for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg tablet of DIO-902 once daily for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg DIO-902 tablet daily for 16 weeks
Study NCT00494663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg DIO-902 tablet for 16 weeks
Study NCT02198196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Talk-Mindfulness
Study NCT02532036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled MVA85A
Study NCT02532036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular MVA85A
Study NCT03955562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparison villages
Description: Villages that do not receive a footbridge.
Study NCT02532036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular Saline placebo
Study NCT02532036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosol inhaled Saline placebo
Study NCT02732639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (PEG-IFN) alfa-2a
Description: Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
Study NCT01618253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
Study NCT01618253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional fractionation (2 Gy per day) external beam radiation therapy
Description: Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced.
Study NCT02075476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Study NCT02075476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse arthroplasty
Study NCT06042322 — intervention group
Intervention type: OTHER
Intervention: Educational intervention
Description: Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
Study NCT04630041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 211 Referral
Description: Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
Study NCT02116790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Subjects will take one 250mg Naproxen capsule
Study NCT02116790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet
Description: Subjects will take one 12.5mg/50mg Sinemet.
Study NCT02116790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet
Description: Subjects will take one 25mg/100mg Sinemet.
Study NCT02116790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two placebos.
Study NCT01195948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B27PD
Study NCT02860936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
Study NCT01670864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
Study NCT01670864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS intervention group
Description: The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
Study NCT03377465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
Description: ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
Study NCT03377465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
Description: ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
Study NCT03540862 — intervention group
Intervention type: DEVICE
Intervention: maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)
Description: hospital-based NPV once every week as the maintenance program
Study NCT02415530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined home visiting and group intervention
Description: home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3\~6 months
Study NCT02415530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT01959100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 250 mg x 3/week per os during a meal for a period of 2 years
Study NCT01959100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mg x 3/week during a meal for a period of 2 years
Study NCT03613493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Description: The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.